药明合联的受托人于2026年5月19日至29日期间,在公开市场进行了一系列股份回购。数据显示,此次回购行动共涉及570万股股份,总耗资约3.265亿港元。经计算,平均每股回购价格约为57.3港元。这一举措通常被视为公司对自身未来发展抱有信心的信号,也可能旨在提升股东价值或优化资本结构。
药明合联的受托人于2026年5月19日至29日期间,在公开市场进行了一系列股份回购。数据显示,此次回购行动共涉及570万股股份,总耗资约3.265亿港元。经计算,平均每股回购价格约为57.3港元。这一举措通常被视为公司对自身未来发展抱有信心的信号,也可能旨在提升股东价值或优化资本结构。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.